<DOC>
	<DOCNO>NCT02717611</DOCNO>
	<brief_summary>A Phase 2 Study evaluate Efficacy Safety ACP-196 ( acalabrutinib ) Subjects Relapsed/Refractory CLL Intolerant Ibrutinib Therapy</brief_summary>
	<brief_title>A Study ACP-196 ( Acalabrutinib ) Subjects With Relapsed/Refractory CLL Intolerant Ibrutinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age . 2 . Prior diagnosis CLL 3 . Must receive ≥ 1 prior therapy CLL 4 . Intolerant ibrutinib 5 . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty . 6 . ECOG performance status ≤ 2 . 1 . Ongoing AE attribute ibrutinib therapy 2 . Treatment systemic anticancer therapy CLL prohibit discontinuation ibrutinib enrollment trial . 3 . Prior exposure BCL2 inhibitor ( eg , venetoclax/ABT199 ) 4 . Prior malignancy ( CLL ) , except adequately treat basal cell squamous cell skin cancer , situ cancer , cancer subject disease free ≥ 2 year . 5 . Significant cardiovascular disease uncontrolled symptomatic untreated arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , QTc &gt; 480 msec screening . Exception : Subjects control , asymptomatic atrial fibrillation screening allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ibrutinib Intolerant</keyword>
</DOC>